PeptideSkincare
Peptide Science

Peptides for Menopause: What the Skin Research Actually Shows

By · Published November 6, 2026 · Updated November 3, 2026 · 14 min read

Start with our pillar guide: Best Peptides for Skin: Peptide Ingredients in Skincare Ranked by Evidence, or browse all Peptide Science articles.

Peptides for menopause are not a menopause treatment. They don't replace estrogen or hormone therapy, and they don't balance hormones. What research suggests is narrower. Some topical peptides may modestly improve the look of fine lines in general groups of adult women (Robinson et al., 2005). Oral collagen peptides gave mixed results for hydration and elasticity (Pu et al., 2023; Myung and Park, 2025). In the abstracts we reviewed, almost no peptide study enrolled women selected for menopause.

Evidence: Limited.

This guide covers skincare peptides and collagen peptides, not injectable peptides sold by clinics, which are drugs rather than cosmetics and a different category outside this page; ask your clinician about them.

This page is part of our menopause skin series. The series hub, our menopause skin care guide, covers skin changes more broadly. For peptide types and how they work in general, see what peptides do for your skin. Here we look only at peptides and menopausal skin: what has been tested, in whom, and who paid for it.

Key takeaways

  • The one topical peptide study framed around menopausal skin was a developer-run study of 32 women with no control group described (Falla and Zhang, 2010).
  • In a 12-week split-face trial of 93 women aged 35 to 55, a moisturizer with palmitoyl pentapeptide reduced wrinkles and fine lines more than the same moisturizer without it. All authors worked for Procter & Gamble (Robinson et al., 2005).
  • In the largest review we found, only 2 of 19 peptide trials tested a topical product. Most of the benefit came from oral collagen-type peptides (Nukaly et al., 2026).
  • Oral collagen trials in menopausal women disagree: one found gains vs baseline, another found no benefit (Duangjai et al., 2025; Guadanhim et al., 2023).
  • In a lab test by FDA scientists, a common anti-wrinkle peptide mostly washed off the skin, and none reached the dermis (Kraeling et al., 2015).

Can peptides for menopause help your skin?

Possibly, but only modestly, and mostly in studies that didn't select women for menopause. A 2024 systematic review of 9 topical peptide articles found improvements in fine lines, elasticity and texture in early trials. It called the data "preliminary" and noted that peptides are not FDA approved; the authors declared no conflicts and no funding (Ash et al., 2024). Evidence: Limited.

Our overall verdict is therefore a judgment, not a trial result. Peptides may be a reasonable cosmetic option for the look of fine lines. They are not a way to treat menopause or replace hormones. Evidence: Expert opinion.

Why does skin change at menopause?

A review explains that losing estrogen after menopause makes skin thinner, with less collagen, less elasticity, more wrinkling and more dryness (Thornton, 2013; funding not stated). Our menopause skin care guide covers these changes in detail. Evidence: Expert opinion.

What is a peptide, and what is it not?

A peptide is a short chain of amino acids, the building blocks of proteins. Skincare uses signal, carrier and neurotransmitter-inhibiting peptides, plus collagen peptides taken by mouth; our pillar guide on what peptides do for your skin explains each group. Skincare peptides are cosmetic ingredients, not hormones, and not FDA-approved drugs (Ash et al., 2024). Evidence: Limited.

Getting into skin is also a hurdle. In a lab test on human cadaver skin, most acetyl hexapeptide-8 washed off the surface. Only 0.22% reached the stratum corneum (the outer layer), 0.01% reached the epidermis, and none was found in the dermis (Kraeling et al., 2015; authors at the US FDA). Evidence: Early-preliminary (lab).

What studies of peptides for menopause actually exist?

Very few, in the abstracts we reviewed. Here is what we found.

A company study of hexapeptide-7. The one topical peptide study framed around menopausal skin reported 32 women with an average age of 54; its abstract doesn't describe a control group or give figures. Both authors worked at Helix BioMedix Inc., the company that developed the peptide. In cell tests, the peptide raised skin-cell growth and collagen production. In the women, forehead wrinkles and texture were described as "improved". The abstract does not give the study length or menopause status, and it calls the peptide "Heptapeptide-7" in one place (Falla and Zhang, 2010). Evidence: Early-preliminary.

An expert panel. A 2026 round table of a gynecologist, a plastic surgeon and two dermatologists listed signal peptides among topical options for menopausal skin. The same panel ranked hormone replacement therapy, topical estrogen, two injectable treatments (poly-L-lactic acid and hyaluronic acid) and CO2 laser resurfacing as most effective. The activity was supported by an educational grant from AbbVie and Galderma. Panelists report consulting or research ties to companies including AbbVie/Allergan, Galderma, Merz, L'Oréal and RoC, and the lead author holds stock in Allergan Aesthetics and Revance (Fabi et al., 2026). Evidence: Expert opinion.

A growth-factor serum (not a peptide). In 17 postmenopausal women, a growth-factor serum improved lines, tone and roughness vs baseline over 12 weeks. Growth factors are not peptides, and this study was open-label with no control group. It was run with the serum's maker, Allergan Aesthetics, an AbbVie company (Gold et al., 2023). Evidence: Early-preliminary.

In the abstracts we reviewed, we found no vehicle-controlled trial of a topical peptide in women selected for menopause.

What does the general topical peptide research show?

None of these studies selected women for menopause.

  • Palmitoyl pentapeptide (pal-KTTKS). 93 women aged 35 to 55, 12 weeks, double-blind, split-face. The peptide moisturizer reduced wrinkles and fine lines more than the same moisturizer without the peptide, and it was well tolerated. The abstract gives no effect sizes. All authors worked for Procter & Gamble (Robinson et al., 2005). Evidence: Limited.
  • A multi-ingredient regimen. In 196 women, a three-product regimen with niacinamide, peptides and retinyl propionate improved wrinkle appearance more than a prescription tretinoin regimen at 8 weeks. Results were comparable at 24 weeks in a smaller continuation group (48 of 50 completed), and the regimen was better tolerated. The study was funded by Procter & Gamble Beauty; 5 authors were P&G employees and 6 were paid P&G consultants (full text). Because the products had several actives, the peptide's share of the effect can't be isolated (Fu et al., 2010). Evidence: Limited.
  • A biopsy patch test. In 9 people with sun-damaged skin, a commercial cream with peptides and other actives, applied under occlusion for 12 days, raised fibrillin-1 and procollagen I in biopsies. These are lab markers, not visible results. Funding is not stated in PubMed (Watson et al., 2008). Evidence: Early-preliminary.
  • Reviews disagree on strength. One systematic review rated the peptide evidence "the strongest" among cosmeceuticals for sun-damaged skin. That grading is the authors' own, and several authors work in private aesthetic clinics (Chan et al., 2024). A 2025 review of GHK peptides found a "surprising absence of clinical studies" (Mortazavi et al., 2025; no conflicts declared). Evidence: Expert opinion.
  • The largest meta-analysis. Across 19 randomized trials (1,341 people), peptides gave a modest pooled wrinkle effect (MD 0.27, p = 0.04), driven by oral peptides. Effects on elasticity and density were inconsistent. Only 2 of the 19 trials tested a topical product. The authors report no funding and no conflicts (Nukaly et al., 2026). Evidence: Moderate (oral); Limited (topical).

What are the best peptides for menopause?

No single peptide stands out for menopausal skin. The table below ranks peptide types by what was tested and in whom, not by product.

Peptide type What was tested Menopause-selected? Evidence label Studies
Palmitoyl pentapeptide (pal-KTTKS) Wrinkles, 93 women aged 35–55; all authors P&G No Limited Robinson et al., 2005
Multi-peptide + niacinamide regimens Wrinkles vs a prescription regimen, 196 women; P&G funded No Limited (can't isolate the peptide) Fu et al., 2010
Hexapeptide-7 Wrinkles and texture, 32 women, mean age 54; developer's study Not stated Early-preliminary Falla and Zhang, 2010
Copper peptide (GHK-Cu) Lab and gene data; 13-patient post-laser trial with no objective benefit No Early-preliminary (lab) / Limited Mortazavi et al., 2025; Pickart and Margolina, 2018; Miller et al., 2006
Acetyl hexapeptide-8 Skin penetration only, in a lab No Early-preliminary (lab) Kraeling et al., 2015
Oral collagen peptides Hydration and elasticity Yes (two trials) plus general groups Limited to Moderate, mixed Duangjai et al., 2025; Guadanhim et al., 2023; Nukaly et al., 2026; Myung and Park, 2025; Pu et al., 2023
Growth factors (not peptides) Lines and tone, 17 postmenopausal women, open-label; maker-run Yes Early-preliminary Gold et al., 2023

Many peptide studies were run or funded by the companies that make the products.

Do copper peptides help menopausal skin?

Copper peptides (GHK-Cu) have broad lab support but little clinical data. A gene-data review reports that GHK raises collagen, elastin and glycosaminoglycan production. Both authors list R&D Skin Biology, a company, as their affiliation; the paper declares no external funding and no conflicts (Pickart and Margolina, 2018). Evidence: Early-preliminary (lab).

Another review notes a "surprising absence of clinical studies" of GHK-Cu and its palmitoyl form (Mortazavi et al., 2025). In a trial where 13 patients completed after CO2 laser resurfacing, GHK-Cu products gave no objective difference in redness, wrinkles or skin quality. Patients using them did report higher satisfaction (p = .04). Funding is not stated in PubMed (Miller et al., 2006). Evidence: Limited.

In the abstracts we reviewed, we found no clinical trial of copper peptides (GHK-Cu) in menopausal women. Our guide to copper peptides for skin covers GHK-Cu in more depth. For hair, see menopause hair loss.

Do oral collagen peptides help menopausal skin?

Oral collagen trials in menopausal women disagree: one found gains vs baseline, another found no benefit.

  • Positive vs baseline. In a four-arm randomized trial in menopausal women (80 enrolled, 79 completed, per the full text), six months of collagen plus calcium and vitamin D raised hydration by 23% and elasticity by 8.52% compared with baseline. Collagen alone raised elasticity by 12.23% vs baseline. Water loss through the skin did not change. These are mostly within-group changes, not comparisons with placebo. The trial had a Thai government grant, and the collagen came from the authors' own university center; the authors declare no conflicts (Duangjai et al., 2025). Evidence: Limited.
  • No benefit. In a double-blind trial of 56 postmenopausal women aged 60 to 93 with fragile forearm skin, six months of oral or topical collagen, alone or together, showed no significant difference on any outcome (p > 0.1). Its funding statements conflict: one says it had none, and another names a university support foundation (FAP-UNIFESP). No company funding is reported, and the authors declare no competing interests (Guadanhim et al., 2023). Evidence: Moderate.

In general groups, a meta-analysis of 26 trials (1,721 patients) found hydrolyzed collagen improved hydration and elasticity vs placebo, while noting biases in the trials; it was funded by a hospital grant (Pu et al., 2023). A 2025 meta-analysis of 23 trials (1,474 participants) found a benefit when all trials were pooled, but no effect in trials not funded by pharmaceutical companies or in high-quality trials; its funding is not stated in PubMed (Myung and Park, 2025). Evidence: Moderate.

Our collagen supplements guide covers this research in full. A dedicated page is on the way: our collagen for menopause guide.

Are peptides for menopause safe to use?

In the trials we reviewed, peptides were well tolerated, with minimal side effects (Nukaly et al., 2026; Robinson et al., 2005; Fu et al., 2010). Lab data also suggest that little of a topical peptide gets past the skin's outer layers (Kraeling et al., 2015). Evidence: Limited.

But those trials were short, and most did not enroll menopausal women. In the abstracts we reviewed, no study compared peptides with estrogen or hormone therapy, and none tracked long-term safety in menopausal women. Peptides are not hormones, and the reviewed studies give no reason to think they act like estrogen. Their use alongside hormone therapy has not been studied, so ask your clinician if you are unsure.

If you choose to try a topical peptide product, general skincare sense applies:

  1. Patch test first. Try a small amount on a small area for a few days. Evidence: Expert opinion.
  2. Add one new product at a time. That way you can tell what causes a reaction. Evidence: Expert opinion.
  3. Stop the product if irritation appears. See a clinician if it doesn't settle. Evidence: Expert opinion.
  4. Keep the basics. Gentle cleansing, moisturizer and sunscreen support a dry, thinning barrier; see our guide to hydration and the skin barrier. Evidence: Expert opinion.
  5. Judge results over months, not days. The trials ran 8 to 24 weeks (Robinson et al., 2005; Fu et al., 2010). Evidence: Limited.

Where do peptides for menopause fit next to retinol and hormones?

For how peptides compare with retinoids on menopausal skin, see our guide to peptides vs retinol. For questions about estrogen, hormone therapy and skin, see our page on estrogen cream for the face, and ask your clinician before any decision about hormones.

Part of our menopause skin series

Where the evidence stops

  • In the abstracts we reviewed, we found no vehicle-controlled trial of a topical peptide, or clinical trial of copper peptides, in women selected for menopause.
  • No study we reviewed compared peptides with estrogen or hormone therapy or tracked long-term safety in menopausal women.
  • Many peptide studies were run or funded by the companies that make the products.

FAQ

Do peptides help menopause skin?

Possibly, but only in a narrow way. Some topical peptides modestly improved the look of fine lines in trials of general groups of adult women. Those trials did not select women for menopause. In the abstracts we reviewed, we found no vehicle-controlled trial of a topical peptide in women selected for menopause. Any benefit for menopausal skin is an assumption, not a tested result.

What are the best peptides for menopause?

No peptide has strong evidence for menopausal skin. Palmitoyl pentapeptide has one industry-run trial in 93 women aged 35 to 55. Multi-peptide regimens have industry-funded trials that cannot isolate the peptide. Copper peptides rest mostly on lab data. Oral collagen peptides are the only type tested in women selected for menopause, and those results were mixed.

Can peptides replace estrogen or HRT?

No. Skincare peptides are cosmetic ingredients, not hormones, and they are not a substitute for estrogen or hormone therapy. In the abstracts we reviewed, no study compared peptides with estrogen or hormone therapy. Questions about hormone therapy, including whether it fits you, belong with your clinician.

Do peptides balance hormones?

The studies we reviewed give no evidence that skincare peptides change hormone levels. The trials measured wrinkles, texture, hydration and elasticity, not hormones. Skincare peptides are cosmetic ingredients. A lab study by FDA scientists found that one common peptide mostly stayed on the skin surface and did not reach the deeper skin layer.

Are copper peptides good for menopausal skin?

The evidence is thin. Lab and gene data on GHK-Cu are broad, but one review describes a surprising absence of clinical studies. A 13-patient trial after laser resurfacing found no objective benefit, only higher patient satisfaction. In the abstracts we reviewed, we found no clinical trial of copper peptides in menopausal women.

Do collagen peptides work for menopausal skin?

The results disagree. One six-month trial in menopausal women reported gains in hydration and elasticity compared with baseline. Another six-month trial in postmenopausal women aged 60 to 93 found no benefit on forearm skin. A large review found no effect in high-quality trials or trials not funded by pharmaceutical companies.

Are peptides safe to use during menopause?

Topical peptides were well tolerated, with minimal side effects, in the trials we reviewed. But those trials were short and mostly did not enroll menopausal women. We found no long-term or menopause-specific safety data. Patch testing a new product and stopping it if irritation appears are sensible general precautions.

What about injectable peptide therapy for menopause?

This guide does not cover it. Injectable peptides offered by clinics are drugs, not cosmetics. They are a separate category from the skincare and collagen peptides discussed here. Ask your clinician about them.

References

  1. Falla TJ, Zhang L. Efficacy of hexapeptide-7 on menopausal skin. J Drugs Dermatol. 2010. Cell and microarray work plus a clinical study of 32 women (design, control and duration not reported in abstract); both authors at Helix BioMedix Inc., the peptide's developer; conflicts not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/20120425/
  2. Fabi, et al. Round Table Discussion: Aesthetic Treatment Considerations for the Perimenopausal & Menopausal Patient. J Cosmet Dermatol. 2026. Expert round table (5 authors; panel of a gynecologist, a plastic surgeon and two dermatologists); supported by an educational grant from AbbVie and Galderma; panelists report ties to AbbVie/Allergan, Galderma, Merz, L'Oréal, RoC and others; the lead author holds stock in Allergan Aesthetics and Revance; one is a researcher for Alloy Women's Health. https://pubmed.ncbi.nlm.nih.gov/41461019/
  3. Gold, et al. Improvements in skin quality parameters in postmenopausal participants after use of topical growth factor serum. J Cosmet Dermatol. 2023. Open-label, uncontrolled study, 17 postmenopausal women; growth-factor serum, not a peptide; affiliation with Allergan Aesthetics (AbbVie), the product's maker. https://pubmed.ncbi.nlm.nih.gov/36237142/
  4. Thornton. Estrogens and aging skin. Dermatoendocrinol. 2013. Review; funding and conflicts not stated. https://pubmed.ncbi.nlm.nih.gov/24194966/
  5. Ash, et al. The Innovative and Evolving Landscape of Topical Exosome and Peptide Therapies: A Systematic Review of the Available Literature. Aesthet Surg J Open Forum. 2024. Systematic review, 9 peptide articles; no financial support; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/38633728/
  6. Kraeling, et al. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015. Lab penetration study, guinea-pig and human cadaver skin; authors at the US FDA (CFSAN). https://pubmed.ncbi.nlm.nih.gov/24754410/
  7. Robinson, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005. Double-blind split-face randomized trial, 93 women aged 35–55; all authors at Procter & Gamble. https://pubmed.ncbi.nlm.nih.gov/18492182/
  8. Fu, et al. A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen. Br J Dermatol. 2010. Randomized parallel trial, 196 women; funded by Procter & Gamble Beauty; 5 authors P&G employees and 6 paid P&G consultants. https://pubmed.ncbi.nlm.nih.gov/20374604/
  9. Watson, et al. Repair of photoaged dermal matrix by topical application of a cosmetic 'antiageing' product. Br J Dermatol. 2008. Occluded patch-test randomized trial, 9 volunteers; tested a commercial cream; funding not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/18070204/
  10. Chan, et al. Cosmeceuticals in photoaging: A review. Skin Res Technol. 2024. Systematic review; generic conflict-of-interest certification only; no funding statement; several authors at private aesthetic clinics. https://pubmed.ncbi.nlm.nih.gov/39233460/
  11. Mortazavi, et al. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2025. Review; no conflicts declared; funding not applicable. https://pubmed.ncbi.nlm.nih.gov/39963574/
  12. Nukaly, et al. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2026. Systematic review and meta-analysis, 19 trials, 1,341 participants (17 oral, 2 topical); no funding; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/41924746/
  13. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. Review of gene-expression data; no external funding and no conflicts declared; both authors list R&D Skin Biology, a company. https://pubmed.ncbi.nlm.nih.gov/29986520/
  14. Miller, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. Randomized trial, 13 patients completed; funding not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/16847171/
  15. Duangjai, et al. Calcium and Vitamin D Supplementation with and Without Collagen on Bone Density and Skin Elasticity in Menopausal Women-A Randomized Controlled Study. Clin Pract. 2025. Four-arm randomized trial, 80 menopausal women (79 completed); Thai government PMUC grant; collagen supplied by the authors' own university center; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/41002783/
  16. Guadanhim, et al. Efficacy and Safety of Topical or Oral Hydrolyzed Collagen in Women with Dermatoporosis: A Randomized, Double-Blind, Factorial Design Study. Dermatol Ther (Heidelb). 2023. Double-blind factorial randomized trial, 56 postmenopausal women; funding statements conflict (none vs. Fundação de Apoio à UNIFESP, a university support foundation); no company funding reported; no competing interests. https://pubmed.ncbi.nlm.nih.gov/36547800/
  17. Pu, et al. Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis. Nutrients. 2023. Systematic review and meta-analysis, 26 trials, 1,721 patients; Wan Fang Hospital grant; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/37432180/
  18. Myung SK, Park Y. Effects of Collagen Supplements on Skin Aging: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Med. 2025. Systematic review and meta-analysis, 23 trials, 1,474 participants; funding not stated in PubMed. https://pubmed.ncbi.nlm.nih.gov/40324552/

For educational purposes only; not medical advice. See our disclaimer and research method.